What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
Elihu H. Estey mainly investigates Internal medicine, Leukemia, Myeloid leukemia, Immunology and Surgery.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology.
Leukemia is often connected to Cancer research in his work.
His Myeloid leukemia research is multidisciplinary, incorporating elements of Cancer, Performance status, Fms-Like Tyrosine Kinase 3 and Bone marrow.
His work on Chronic myelomonocytic leukemia as part of general Immunology research is frequently linked to In patient, bridging the gap between disciplines.
His study looks at the intersection of Surgery and topics like Chlorodeoxyadenosine with Waldenstrom macroglobulinemia.
His most cited work include:
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2438 citations)
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2097 citations)
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2002 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Myeloid leukemia, Oncology, Leukemia and Gastroenterology.
He combines subjects such as Surgery and Immunology with his study of Internal medicine.
His Myeloid leukemia research is multidisciplinary, incorporating perspectives in Cancer, Disease, Bone marrow and Cytogenetics.
His research in Oncology tackles topics such as Clinical trial which are related to areas like Intensive care medicine.
Elihu H. Estey interconnects Myeloid, Pharmacology and Survival rate in the investigation of issues within Leukemia.
His Gastroenterology research incorporates elements of Myelodysplastic syndromes and Toxicity, Phases of clinical research.
He most often published in these fields:
- Internal medicine (94.02%)
- Myeloid leukemia (57.34%)
- Oncology (48.64%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (94.02%)
- Myeloid leukemia (57.34%)
- Oncology (48.64%)
In recent papers he was focusing on the following fields of study:
Elihu H. Estey focuses on Internal medicine, Myeloid leukemia, Oncology, Myeloid and Leukemia.
His study connects Gastroenterology and Internal medicine.
His Myeloid leukemia research integrates issues from Mitoxantrone, Newly diagnosed and Hematopoietic stem cell transplantation, Disease.
The Oncology study combines topics in areas such as Clinical trial, Complete remission, Decitabine, Hazard ratio and Myeloid Neoplasm.
He has researched Myeloid in several fields, including Young adult, Cancer and MEDLINE.
His studies deal with areas such as Logistic regression and Drug resistance as well as Leukemia.
Between 2016 and 2021, his most popular works were:
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2002 citations)
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet (134 citations)
- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial (119 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
His main research concerns Myeloid leukemia, Internal medicine, Oncology, Leukemia and Myeloid.
His Myeloid leukemia study combines topics from a wide range of disciplines, such as Clinical trial, Disease, Transplantation and Intensive care medicine.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Cytogenetics.
Elihu H. Estey works mostly in the field of Oncology, limiting it down to concerns involving Hazard ratio and, occasionally, Proportional hazards model.
His research investigates the link between Leukemia and topics such as Surgery that cross with problems in White blood cell.
His Myeloid research includes elements of Cancer, Performance status, Mitoxantrone, Survival rate and Drug resistance.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
